Cargando…

Metabolomic approach to evaluating adriamycin pharmacodynamics and resistance in breast cancer cells

Continuous exposure of breast cancer cells to adriamycin induces high expression of P-gp and multiple drug resistance. However, the biochemical process and the underlying mechanisms for the gradually induced resistance are not clear. To explore the underlying mechanism and evaluate the anti-tumor ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Bei, Li, Mengjie, Zha, Weibin, Zhao, Qijin, Gu, Rongrong, Liu, Linsheng, Shi, Jian, Zhou, Jun, Zhou, Fang, Wu, Xiaolan, Wu, Zimei, Wang, Guangji, Aa, Jiye
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3769585/
https://www.ncbi.nlm.nih.gov/pubmed/24039617
http://dx.doi.org/10.1007/s11306-013-0517-x
_version_ 1782284001400061952
author Cao, Bei
Li, Mengjie
Zha, Weibin
Zhao, Qijin
Gu, Rongrong
Liu, Linsheng
Shi, Jian
Zhou, Jun
Zhou, Fang
Wu, Xiaolan
Wu, Zimei
Wang, Guangji
Aa, Jiye
author_facet Cao, Bei
Li, Mengjie
Zha, Weibin
Zhao, Qijin
Gu, Rongrong
Liu, Linsheng
Shi, Jian
Zhou, Jun
Zhou, Fang
Wu, Xiaolan
Wu, Zimei
Wang, Guangji
Aa, Jiye
author_sort Cao, Bei
collection PubMed
description Continuous exposure of breast cancer cells to adriamycin induces high expression of P-gp and multiple drug resistance. However, the biochemical process and the underlying mechanisms for the gradually induced resistance are not clear. To explore the underlying mechanism and evaluate the anti-tumor effect and resistance of adriamycin, the drug-sensitive MCF-7S and the drug-resistant MCF-7Adr breast cancer cells were used and treated with adriamycin, and the intracellular metabolites were profiled using gas chromatography mass spectrometry. Principal components analysis of the data revealed that the two cell lines showed distinctly different metabolic responses to adriamycin. Adriamycin exposure significantly altered metabolic pattern of MCF-7S cells, which gradually became similar to the pattern of MCF-7Adr, indicating that metabolic shifts were involved in adriamycin resistance. Many intracellular metabolites involved in various metabolic pathways were significantly modulated by adriamycin treatment in the drug-sensitive MCF-7S cells, but were much less affected in the drug-resistant MCF-7Adr cells. Adriamycin treatment markedly depressed the biosynthesis of proteins, purines, pyrimidines and glutathione, and glycolysis, while it enhanced glycerol metabolism of MCF-7S cells. The elevated glycerol metabolism and down-regulated glutathione biosynthesis suggested an increased reactive oxygen species (ROS) generation and a weakened ability to balance ROS, respectively. Further studies revealed that adriamycin increased ROS and up-regulated P-gp in MCF-7S cells, which could be reversed by N-acetylcysteine treatment. It is suggested that adriamycin resistance is involved in slowed metabolism and aggravated oxidative stress. Assessment of cellular metabolomics and metabolic markers may be used to evaluate anti-tumor effects and to screen for candidate anti-tumor agents. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s11306-013-0517-x) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-3769585
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-37695852013-09-13 Metabolomic approach to evaluating adriamycin pharmacodynamics and resistance in breast cancer cells Cao, Bei Li, Mengjie Zha, Weibin Zhao, Qijin Gu, Rongrong Liu, Linsheng Shi, Jian Zhou, Jun Zhou, Fang Wu, Xiaolan Wu, Zimei Wang, Guangji Aa, Jiye Metabolomics Original Article Continuous exposure of breast cancer cells to adriamycin induces high expression of P-gp and multiple drug resistance. However, the biochemical process and the underlying mechanisms for the gradually induced resistance are not clear. To explore the underlying mechanism and evaluate the anti-tumor effect and resistance of adriamycin, the drug-sensitive MCF-7S and the drug-resistant MCF-7Adr breast cancer cells were used and treated with adriamycin, and the intracellular metabolites were profiled using gas chromatography mass spectrometry. Principal components analysis of the data revealed that the two cell lines showed distinctly different metabolic responses to adriamycin. Adriamycin exposure significantly altered metabolic pattern of MCF-7S cells, which gradually became similar to the pattern of MCF-7Adr, indicating that metabolic shifts were involved in adriamycin resistance. Many intracellular metabolites involved in various metabolic pathways were significantly modulated by adriamycin treatment in the drug-sensitive MCF-7S cells, but were much less affected in the drug-resistant MCF-7Adr cells. Adriamycin treatment markedly depressed the biosynthesis of proteins, purines, pyrimidines and glutathione, and glycolysis, while it enhanced glycerol metabolism of MCF-7S cells. The elevated glycerol metabolism and down-regulated glutathione biosynthesis suggested an increased reactive oxygen species (ROS) generation and a weakened ability to balance ROS, respectively. Further studies revealed that adriamycin increased ROS and up-regulated P-gp in MCF-7S cells, which could be reversed by N-acetylcysteine treatment. It is suggested that adriamycin resistance is involved in slowed metabolism and aggravated oxidative stress. Assessment of cellular metabolomics and metabolic markers may be used to evaluate anti-tumor effects and to screen for candidate anti-tumor agents. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s11306-013-0517-x) contains supplementary material, which is available to authorized users. Springer US 2013-03-20 2013 /pmc/articles/PMC3769585/ /pubmed/24039617 http://dx.doi.org/10.1007/s11306-013-0517-x Text en © The Author(s) 2013 https://creativecommons.org/licenses/by/2.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Original Article
Cao, Bei
Li, Mengjie
Zha, Weibin
Zhao, Qijin
Gu, Rongrong
Liu, Linsheng
Shi, Jian
Zhou, Jun
Zhou, Fang
Wu, Xiaolan
Wu, Zimei
Wang, Guangji
Aa, Jiye
Metabolomic approach to evaluating adriamycin pharmacodynamics and resistance in breast cancer cells
title Metabolomic approach to evaluating adriamycin pharmacodynamics and resistance in breast cancer cells
title_full Metabolomic approach to evaluating adriamycin pharmacodynamics and resistance in breast cancer cells
title_fullStr Metabolomic approach to evaluating adriamycin pharmacodynamics and resistance in breast cancer cells
title_full_unstemmed Metabolomic approach to evaluating adriamycin pharmacodynamics and resistance in breast cancer cells
title_short Metabolomic approach to evaluating adriamycin pharmacodynamics and resistance in breast cancer cells
title_sort metabolomic approach to evaluating adriamycin pharmacodynamics and resistance in breast cancer cells
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3769585/
https://www.ncbi.nlm.nih.gov/pubmed/24039617
http://dx.doi.org/10.1007/s11306-013-0517-x
work_keys_str_mv AT caobei metabolomicapproachtoevaluatingadriamycinpharmacodynamicsandresistanceinbreastcancercells
AT limengjie metabolomicapproachtoevaluatingadriamycinpharmacodynamicsandresistanceinbreastcancercells
AT zhaweibin metabolomicapproachtoevaluatingadriamycinpharmacodynamicsandresistanceinbreastcancercells
AT zhaoqijin metabolomicapproachtoevaluatingadriamycinpharmacodynamicsandresistanceinbreastcancercells
AT gurongrong metabolomicapproachtoevaluatingadriamycinpharmacodynamicsandresistanceinbreastcancercells
AT liulinsheng metabolomicapproachtoevaluatingadriamycinpharmacodynamicsandresistanceinbreastcancercells
AT shijian metabolomicapproachtoevaluatingadriamycinpharmacodynamicsandresistanceinbreastcancercells
AT zhoujun metabolomicapproachtoevaluatingadriamycinpharmacodynamicsandresistanceinbreastcancercells
AT zhoufang metabolomicapproachtoevaluatingadriamycinpharmacodynamicsandresistanceinbreastcancercells
AT wuxiaolan metabolomicapproachtoevaluatingadriamycinpharmacodynamicsandresistanceinbreastcancercells
AT wuzimei metabolomicapproachtoevaluatingadriamycinpharmacodynamicsandresistanceinbreastcancercells
AT wangguangji metabolomicapproachtoevaluatingadriamycinpharmacodynamicsandresistanceinbreastcancercells
AT aajiye metabolomicapproachtoevaluatingadriamycinpharmacodynamicsandresistanceinbreastcancercells